文献速递呼吸道感染呼吸危重症与机械通气

替沙格韦单抗-西加韦单抗治疗COVID-19住院患者的随机双盲3期试验

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2022-07-08

这项随机双盲3期试验纳入1455例COVID-19住院患者,比较替沙格韦单抗-西加韦单抗与安慰剂(均联合瑞德西韦及标准治疗)。

核心结论

  • 在COVID-19住院患者中,替沙格韦单抗-西加韦单抗未改善持续恢复时间,但安全性良好且死亡率较低。

研究设计与样本

  • 随机、双盲、3期、安慰剂对照试验,在美国、欧洲、乌干达和新加坡81个中心进行。
  • 1455例有症状≤12天且住院的COVID-19成人随机1:1接受静脉替沙格韦单抗300 mg-西加韦单抗300 mg或安慰剂,均联合瑞德西韦及标准治疗。
  • 排除急性器官衰竭(包括有创机械通气、ECMO、血管加压药、机械循环支持或新肾脏替代治疗)患者。
  • 主要终点为至第90天持续恢复时间(出院后连续14天在家),在意向治疗人群中分析。

主要发现

  • 严重不良事件:单抗组34例(5%),安慰剂组38例(5%)。

临床怎么用

  • 对于接受瑞德西韦及标准治疗的COVID-19住院患者,该单抗组合未显示改善持续恢复时间,但死亡率较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tixagevimab-cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab-cilgavimab versus placebo, in patients receiving remdesivir and other standard care. METHODS: In a randomised, double-blind, phase 3, placebo-controlled trial, adults with symptoms for up to 12 days and hospitalised for COVID-19 at 81 sites in the USA, Europe, Uganda, and Singapore were randomly assigned in a 1:1 ratio to receive intravenous tixagevimab 300 mg-cilgavimab 300 mg or placebo, in addition to remdesivir and other standard care. Patients were excluded if they had acute organ failure including receipt of invasive mechanical ventilation, extracorporeal membrane oxygenation, vasopressor therapy, mechanical circulatory support, or new renal replacement therapy. The study drug was prepared by an unmasked pharmacist; study participants, site study staff, investigators, and clinical providers were masked to study assignment. The primary outcome was time to sustained recovery up to day 90, defined as 14 consecutive days at home after hospital discharge, with co-primary analyses for the full cohort and for participants who were neutralising antibody-negative at baseline. Efficacy and safety analyses were done in the modified intention-to-treat population, defined as participants who received a complete or partial infusion of tixagevimab-cilgavimab or placebo. This study is registered with ClinicalTrials.gov, NCT04501978 and the participant follow-up is ongoing. FINDINGS: From Feb 10 to Sept 30, 2021, 1455 patients were randomly assigned and 1417 in the primary modified intention-to-treat population were infused with tixagevimab-cilgavimab (n=710) or placebo (n=707). The estimated cumulative incidence of sustained recovery was 89% for tixagevimab-cilgavimab and 86% for placebo group participants at day 90 in the full cohort (recovery rate ratio [RRR] 1·08 [95% CI 0·97-1·20]; p=0·21). Results were similar in the seronegative subgroup (RRR 1·14 [0·97-1·34]; p=0·13). Mortality was lower in the tixagevimab-cilgavimab group (61 [9%]) versus placebo group (86 [12%]; hazard ratio [HR] 0·70 [95% CI 0·50-0·97]; p=0·032). The composite safety outcome occurred in 178 (25%) tixagevimab-cilgavimab and 212 (30%) placebo group participants (HR 0·83 [0·68-1·01]; p=0·059). Serious adverse events occurred in 34 (5%) participants in the tixagevimab-cilgavimab group and 38 (5%) in the placebo group. INTERPRETATION: Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab-cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower. FUNDING: US National Institutes of Health (NIH) and Operation Warp Speed.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022. PMID: 35817072. doi:10.1016/S2213-2600(22)00215-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。